| Montclair Memory Clinic Llc | |
|
70 Park Street Suite 207 Montclair NJ 07042-2960 | |
| (973) 743-4555 | |
| (973) 743-4055 |
| Full Name | Montclair Memory Clinic Llc |
|---|---|
| Speciality | Clinical Neuropsychologist |
| Location | 70 Park Street, Montclair, New Jersey |
| Authorized Official Name and Position | Jacqueline A Rondeau (CLINICAL DIRECTOR) |
| Authorized Official Contact | 9737434555 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Montclair Memory Clinic Llc Po Box 8121 Glen Ridge NJ 07028-8121 Ph: (973) 743-4555 | Montclair Memory Clinic Llc 70 Park Street Suite 207 Montclair NJ 07042-2960 Ph: (973) 743-4555 |
| NPI Number | 1114396835 |
|---|---|
| Provider Enumeration Date | 09/23/2015 |
| Last Update Date | 04/15/2016 |
| Medicare PECOS PAC ID | 5193025906 |
|---|---|
| Medicare Enrollment ID | O20151201001298 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.
The Quantum Group, Inc. (NYSE Amex:QGP) announced financial results for the third quarter of fiscal year 2009 ended July 31, 2009.
The United States is seeing a surge of coronavirus disease (COVID-19) cases in just a couple of days, reporting its second death.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114396835 | NPI | - | NPPES |
| 0051560 | Medicaid | NJ |
| Provider Name | Jacqueline Ann Rondeau |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1285622217 PECOS PAC ID: 1355302472 Enrollment ID: I20041022000125 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.
The Quantum Group, Inc. (NYSE Amex:QGP) announced financial results for the third quarter of fiscal year 2009 ended July 31, 2009.
The United States is seeing a surge of coronavirus disease (COVID-19) cases in just a couple of days, reporting its second death.
› Verified 7 days ago
| Provider Name | Monica R Christian |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1194905042 PECOS PAC ID: 1456537141 Enrollment ID: I20110513000244 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.
The Quantum Group, Inc. (NYSE Amex:QGP) announced financial results for the third quarter of fiscal year 2009 ended July 31, 2009.
The United States is seeing a surge of coronavirus disease (COVID-19) cases in just a couple of days, reporting its second death.
› Verified 7 days ago
| Provider Name | Elizabet Santana Marmon-halm |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1487282901 PECOS PAC ID: 5799116141 Enrollment ID: I20200519001267 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.
The Quantum Group, Inc. (NYSE Amex:QGP) announced financial results for the third quarter of fiscal year 2009 ended July 31, 2009.
The United States is seeing a surge of coronavirus disease (COVID-19) cases in just a couple of days, reporting its second death.
› Verified 7 days ago
| Provider Name | Sarah E Jarocki |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1447769484 PECOS PAC ID: 9830505593 Enrollment ID: I20210304002117 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.
The Quantum Group, Inc. (NYSE Amex:QGP) announced financial results for the third quarter of fiscal year 2009 ended July 31, 2009.
The United States is seeing a surge of coronavirus disease (COVID-19) cases in just a couple of days, reporting its second death.
› Verified 7 days ago
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.
The Quantum Group, Inc. (NYSE Amex:QGP) announced financial results for the third quarter of fiscal year 2009 ended July 31, 2009.
The United States is seeing a surge of coronavirus disease (COVID-19) cases in just a couple of days, reporting its second death.
› Verified 7 days ago
Ascending Wellness And Psychotherapy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 70 Park St Ste 104, Montclair, NJ 07042 Phone: 973-932-0433 Fax: 484-634-2903 | |
Leigh Ann S. Tedesco, Lcsw Llc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 88 Park St, Montclair, NJ 07042 Phone: 973-857-6157 | |
Bug And Bear Designs Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 516 Bloomfield Ave Ste 2, Montclair, NJ 07042 Phone: 561-542-0273 | |
Mind & Body Healing Therapy Center, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 18-20 Lackawanna Plz Ste 200, Montclair, NJ 07042 Phone: 973-988-1496 | |
Emergent Change Counseling & Healing Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 18-20 Lackawanna Plz Ste 300, Montclair, NJ 07042 Phone: 973-671-4309 Fax: 973-629-1778 | |
Innovative Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 Park St, Montclair, NJ 07042 Phone: 973-744-4300 | |
Psychotherapy Associates Of Montclair Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 182 Inwood Ave, Montclair, NJ 07043 Phone: 973-746-5650 Fax: 973-746-5556 |